Research programme: fetal growth retardation gene therapy - Magnus Life ScienceAlternative Names: Fetal growth retardation gene therapy - Magnus Growth
Latest Information Update: 20 Jan 2015
At a glance
- Originator Magnus Life Science; University College London
- Class Gene therapies
- Mechanism of Action Vascular endothelial growth factor A expression stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Fetal growth retardation